Tag: Pemafibrate
-
Repurposed antihypertensive and lipid-lowering drugs show promise against MASLD
New hope for MASLD through drug repurposing Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the world’s most common liver disorder, affecting roughly one in three adults. It involves fat buildup in liver cells and is linked to serious liver outcomes and a heightened risk of cardiovascular mortality. A recent study from the University of…
-
Repurposed Antihypertensive and Lipid-Lowering Drugs Show Promise Against MASLD
MASLD: A Global Liver Disease in Need of Safe, Effective Treatments Metabolic dysfunction-associated steatotic liver disease (MASLD) is now recognized as the world’s most common liver disorder, affecting roughly one in three adults. The disease is characterized by fat buildup in liver cells, which can progress to liver dysfunction and is closely linked to higher…